Advertisement

Topics

Search Results for "Rituximab Patent"

07:03 EST 12th February 2016 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...

India

India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Celltrion files IPR against Genentech

Celltrion Inc. (KOSDAQ:068270) filed an inter partes review (IPR) petition with the U.S. Patent and Trademark Office challenging a patent from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) t...

Rituximab Retreatment after Disease Progression Is Comparable to Rituximab Maintenance Therapy in Patients with Low-Tumor Burden Follicular Lymphoma

In a randomized clinical trial, patients with low–tumor burden follicular lymphoma whose cancer responded to initial treatment with rituximab (Rituxan®) experienced similar disease control regardle...

Rituximab plus chemo may improve outcomes for ALL

Dr Maury talks to ecancertv at ASH 2015 about a randomised trial looking at rituximab in addition to standard chemotherapy to treat patients with acute lymphoblastic leukaemia. The study showed th...

Our £60,000 rituximab fund is still available to be put towards a full-scale clinical trial | 12 September 2015

Øystein Fluge and Olav Mella – they're running the rituximab trials in Norway.

Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study

Long-term Rituximab Maintenance for Follicular Lymphoma

After single-agent rituximab therapy for follicular lymphoma, long-term rituximab maintenance therapy significantly prolonged progression-free but not overall survival in the randomized controlled SAK...

Pivotal clinical trials for rituximab biosimilars

Biosimilars of Roche’s MabThera/Rituxan (rituximab), a chimeric monoclonal antibody are currently under development.

Rituximab + Chemo: New Standard of Care for BCP-ALL?

Adding rituximab to chemotherapy significantly improved event free survival in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Medscape Medical News

Matching PubMed Articles

Patent Deployment Strategies and Patent Value in LED Industry.

This study applies two variables in the measurement of company patent deployment strategies: patent family depth and earn plan ratio. Patent family depth represents the degree to which certain fields ...

Patent Highlights June-July 2015.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Searching bioremediation patents through Cooperative Patent Classification (CPC).

Patent classification systems have traditionally evolved independently at each patent jurisdiction to classify patents handled by their examiners to be able to search previous patents while dealing wi...

Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia.

Rituximab in combination with chemotherapy is an effective treatment of patients (pts) with chronic lymphocytic leukemia (CLL). The most frequent adverse event of rituximab is infusion-related toxicit...

Strategies for stem cell patent applications in the light of recent court cases.

Stem cells offer the prospect of treatments for diseases and injuries that are currently beyond medical science. Although development of these potential medical marvels has been dogged by their contro...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement